<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-75978</identifier>
<setSpec>0213-4853</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Apolipoprotein e4 in dementia with Lewy bodies</dc:title>
<dc:description xml:lang="en">Introduction. There is a strong association betweenthe ¦Å4 allele of apolipoprotein E (APOE) and Alzheimer¡¯sdisease (AD). This converts this allele into a risk factorfor the development of AD. The association between APOE4and dementia with Lewy bodies (DLB) is under discussion.In DLB, the presence of APOE4 has been related with a greateramount of senile plaques and neurofibrillary tangles.Method. This is a case-control study in which the APOEgenotype was determined using the modified PCR techniqueof Wenham in 306 patients with diagnosis of probably AD,NINCDS-ADRDA criteria, 58 cases of probably DLB, McKeithet al. consensus criteria (1996), all of them with SPECT withpathological 123I-FP-CIT and 80 normal controls (NC) havingsimilar age and gender distribution.Results. The frequency of alleles was: DLB group ¦Å4:16%; ¦Å3: 75%; ¦Å2: 9%; AD: ¦Å4: 32%; ¦Å3: 67%; ¦Å2: 1%;and in the normal control group: ¦Å4: 12%; ¦Å3: 83%; ¦Å2:5%. The percentage of alleles in both genders was similarin the three groups.Conclusions. APOE4 percentage in DLB group (16%)was lower than in AD group (32 %), and similar to thecontrol group (12 %). Considering that the presence ofmorphopathological Alzheimer type alterations in DBL,essentially neurofibrillary tangles, is inversely correlatedwith the presence of Parkinsonian signs, this group mayrepresent pure forms of the disease, although the lack ofneuropathological demonstration does not make it possibleto confirm this hypothesis (AU)</dc:description>
<dc:creator>Suarez, A</dc:creator>
<dc:creator>Garc¨ªa-Sol¨ªs, D</dc:creator>
<dc:creator>Carrillo Garc¨ªa, F</dc:creator>
<dc:creator>Mir, P</dc:creator>
<dc:creator>Alberca, R</dc:creator>
<dc:creator>Mill¨¢n, J</dc:creator>
<dc:creator>Serrano- Pozo, A</dc:creator>
<dc:creator>Rodr¨ªguez Uranga, J. J</dc:creator>
<dc:creator>Polo, J</dc:creator>
<dc:creator>Gil N¨¦ciga, E</dc:creator>
<dc:creator>Franco, E</dc:creator>
<dc:creator>P¨¦rez D¨ªaz, H</dc:creator>
<dc:creator>Garc¨ªa, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducci¨®n. Existe una fuerte asociaci¨®n entre el alelo¦Å4 de la apolipoprote¨ªna E (APOE) y enfermedad de Alzheimer(EA), constituyendo este alelo un factor de riesgopara padecer esta enfermedad. Su asociaci¨®n con la demenciacon cuerpos de Lewy (DCL) es objeto de controversia. Enla DCL la presencia de APOE4 se ha relacionado con unamayor carga de placas seniles y degeneraci¨®n neurofibrilar.M¨¦todo. Estudio de casos y controles en el que se determin¨®el genotipo APOE mediante la t¨¦cnica de reacci¨®nen cadena de la polimerasa (PCR) modificada de Wenhamen 306 pacientes diagnosticados de EA probable, criteriosNINCDS-ADRDA, 58 casos de DCL probable, criterios de consensode McKeith et al. (1996), todos ellos con SPECT con 123IFP-CIT patol¨®gico, y 80 controles normales (CN) de edad y distribuci¨®npor sexos similares.Resultados. La frecuencia de alelos fue la siguiente:DCL ¦Å4: 16%; ¦Å3: 75%; ¦Å2: 9%; EA ¦Å4: 32%; ¦Å3: 67%; ¦Å2:1%; CN ¦Å4: 12%; ¦Å3: 83%; ¦Å2: 5%. En los tres grupos la distribuci¨®nde alelos en ambos sexos fue similar.Conclusiones. En la DCL la frecuencia de ¦Å4 (16%) esmuy inferior a la de la EA (32%) y muy pr¨®xima a la cifra delos CN (12%). Teniendo en cuenta que la presencia de alteracionesmorfopatol¨®gicas tipo Alzheimer en la DCL, fundamentalmentedegeneraci¨®n neurofibrilar, se correlacionainversamente con la presencia de signos parkinsonianos, esposible que este grupo represente a las formas puras de laenfermedad, aunque la falta de comprobaci¨®n neuropatol¨®gicano permite confirmar esta hip¨®tesis (AU)</dc:description>
<dc:source>Neurologia;23(3): 152-156, abr. 2008. ilus, tab</dc:source>
<dc:identifier>ibc-75978</dc:identifier>
<dc:title xml:lang="es">Apolipoprote¨ªna e4 en la demencia con cuerpos de Lewy</dc:title>
<dc:subject>^d331</dc:subject>
<dc:subject>^d52268</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28320^s22045</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d34224^s22016</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d24551</dc:subject>
<dc:type>article</dc:type>
<dc:date>200804</dc:date>
</metadata>
</record>
</ibecs-document>
